Education and Training:

• B.A., M.D., The Ohio State University
• Post-Doctoral Training, Vanderbilt University, Walter Reed Army Institute of Research, University of Rochester

Appointments and Positions:

• George Lynn Cross Professor, Department of Medicine, 2005-present.
• Professor, Department of Medicine, University of Oklahoma Health Sciences Center, 1990-present.
• Assistant, Associate, Professor, Department of Medicine, University of Texas Health Science Center at San Antonio, 1970-1990.

National Organizations:

• American Society of Hematology, President, 2005; Director, Clinical Research Training Institute, 2003, 2004; Editor, ASH Self-Assessment Program, 1st Edition, 2002; Mentor Award Study Section Chair, 2006-2007.
• National Heart Lung Blood Institute Strategic Planning Working Group, 2006.

Complete List of Publications:

http://profiles.ouhsc.edu/display/74091​

Most Recent 5 Publications:

• George JN, Morton JM, Liles NW, Nester CM. After the party’s over. NEJM  2017; 376 (1): 74-80
• Page EE, Little DJ, Vesely SK, George JN. Quinine-induced thrombotic microangiopathy. Presenting features and long-term outcomes. Amer J Kidney Dis 2017; 70 (5): 686-695
• Little DJ, Mathias LM, Page EE, Kremer Hovinga JA, Vesely SK, George JN.  Long term kidney outcomes in patients with acquired thrombotic thrombocytopenic purpura. Kidney International    Reports 2017; 2 (6): 1088-1095
• George JN. The remarkable diversity of thrombotic thrombocytopenic purpura. A perspective. Blood Advances 2018; 2 (12): 1510-1516
• Reese JA, Peck JD, Deschamps DR, McIntosh JJ, Knudtson EJ, Terrell, DR, Vesely SK, George JN. Platelet counts during pregnancy. NEJM 2018; 379 (1): 32-43

• The Oklahoma Thrombotic Thrombocytopenic Purpura (TTP) Registry.  This is an inception cohort of all patients with clinically diagnosed TTP, supported by documentation of ADAMTS13 deficiency, in Oklahoma, excluding the Tulsa region, since January 1, 1999.  The Registry is an ongoing study of the etiology, diagnosis, management, and long-term outcomes of patients with TTP.  Current Registry projects include the association of autoimmune etiologies of TTP with other autoimmune disorders, such as systemic lupus erythematosus and long-term neurocognitive outcomes following recovery from acute episodes of TTP.
• Drug-induced thrombocytopenia.  A continuing Registry has been initiated to document the levels of evidence in all published case reports describing patients with drug-induced thrombocytopenia, to create a comprehensive database on our website (www.ouhsc.edu/platelets) that lists all drugs that have been associated with thrombocytopenia and the level of evidence regarding causality.  Continuing research is comparing our data to data on laboratory detection of drug-dependent anti-platelet antibodies.
• Gestational thrombocytopenia. We are working to identify the physiologic mechanisms for lower platelet counts during pregnancy. Platelet counts in all women gradually decrease throughout pregnancy, at approximately the same rate, beginning in the first trimester and reaching their nadir at delivery.  At delivery, 10% of women have platelet count less than 150,000/µL, the lower limit of normal. This is described as gestational thrombocytopenia. Platelet counts decrease to <100,000/µL in less than 1% of women at delivery. Therefore if a woman at delivery has a platelet count <100,000/µL, another cause must be identified. Platelet counts return to normal within 6-8 weeks after delivery.